Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xeplion

- PMLiVE

Sidestep into Crohn’s could help Stelara cope with new competition

Filing for new indication expected before year's end

- PMLiVE

J&J’s share buyback ‘doesn’t prevent acquisitions’

Comes as company reports 7.4% decrease in sales

- PMLiVE

FDA approves Alkermes’ long-acting Abilify

Aristada given the nod as injectable antipsychotic

Allergan logo

Allergan and Gedeon finally get antipsychotic green light

Antipsychotic drug Vryalar launches into increasingly competitive market

- PMLiVE

J&J’s Invokana receives new FDA safety warning

Additional trial data highlights bone problems

- PMLiVE

JWT turns to Oscar nominee for Listerine campaign

Produces short online film and app for J&J's mouthwash brand

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

- PMLiVE

New iPad app helps schizophrenia patients

Research shows the app ‘Wizard’ could aid memory and independence

- PMLiVE

Novartis gets early approval for heart failure drug Entresto

It is the first worldwide indication for the in-class neprilysin inhibitor

- PMLiVE

HIV vaccine from J&J starts human trials

Vaccine provided complete protection in primates for similar infection 

- PMLiVE

Vertex wins FDA approval for cystic fibrosis therapy Orkambi

It is the combination therapy’s first regulatory approval

- PMLiVE

Generic Copaxone launches in US

Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links